Contineum therapeutics initiates patient dosing in phase 1b positron emission tomography (pet) trial of pipe-791

San diego--(business wire)--contineum therapeutics, inc. (nasdaq: ctnm) (contineum or the company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (ni&i) indications, today announced dosing of the first cohort of patients in the pipe-791 phase 1b positron emission tomography (pet) tr.
PET Ratings Summary
PET Quant Ranking